Neoadjuvant therapies, which are administered prior to the primary treatment regimen, are increasingly utilized in the clinic, but data on this strategy for pancreatectomy for pancreatic cancer are limited, according to the study authors. Read more . . .
The use of neoadjuvant chemotherapy (NAC) in patients with pancreatic cancer undergoing pancreatic resection was found to be associated with lower postoperative hospital readmission, according to new data.